Press release
Meibomian gland dysfunction Pipeline Analysis & Clinical Trials, 2025, DelveInsight | Azura Ophthalmics, Santen Pharmaceutical
Meibomian gland dysfunction Pipeline Analysis
According to DelveInsight, the Meibomian Gland Dysfunction pipeline includes 4+ key companies actively engaged in developing 4+ therapeutic candidates for its treatment.
Meibomian gland dysfunction Overview:
Meibomian Gland Dysfunction (MGD) is a long-term ocular disorder in which the eyelid glands produce insufficient oil, destabilizing the tear film and causing dry eye symptoms such as irritation, burning, and blurred vision. The condition often results from gland blockages or thickened secretions, commonly linked to aging, hormonal fluctuations, or associated conditions like rosacea. Diagnosis typically includes evaluating the eyelid margins and tear film, with imaging techniques such as meibography employed to assess gland structure and function.
Download our report @ https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
"Meibomian gland dysfunction Pipeline Insight 2025" report by DelveInsight provides a comprehensive analysis of the ongoing clinical development activities and growth prospects across the Meibomian gland dysfunction Therapeutics Market.
Key Takeaways from the Meibomian gland dysfunction Pipeline Report
*
DelveInsight's Meibomian Gland Dysfunction (MGD) pipeline report highlights an active landscape with 4+ companies advancing 4+ therapies in development for MGD treatment.
*
As of June 2024, Azura Ophthalmics launched a Phase 3 trial (ASTRO study) of AZR-MD-001, a selenium sulfide-based ophthalmic ointment designed to restore gland function by relieving blockages and enhancing meibum quality. The trial will assess its safety and efficacy over 12 months.
*
In the same year, the FDA granted 510(k) clearance to the TearCare Registered System for MGD management.
*
Key players such as Azura Ophthalmics, Santen Pharmaceutical, and others are actively evaluating novel therapies, with promising candidates including AZR-MD-001 and additional pipeline drugs.
Meibomian gland dysfunction Pipeline Analysis
The Meibomian gland dysfunction pipeline insights report 2025, provides insights into:
*
Provides comprehensive insights into key companies developing therapies in the Meibomian gland dysfunction Market.
*
Categorizes Meibomian gland dysfunction therapeutic companies by development stage: early, mid, and late-stage.
*
Highlights major companies involved in targeted therapy development, including both active and inactive (paused/discontinued) projects.
*
Reviews emerging Meibomian gland dysfunction drugs under development based on:
*
Stage of development
*
Meibomian gland dysfunction Route of administration
*
Target receptor
*
Monotherapy vs. combination therapy
*
Meibomian gland dysfunction Mechanism of action
*
Molecular type
*
Offers detailed analysis of:
*
Company-to-company and company-academia collaborations
*
Meibomian gland dysfunction Licensing agreements
*
Funding and investment activities supporting future Meibomian gland dysfunction market advancement.
Request for a sample report @ https://www.delveinsight.com/sample-request/meibomian-gland-dysfunction-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr
Meibomian gland dysfunction Emerging Drugs
*
AZR-MD-001: Azura Ophthalmics
Azura's lead candidate, AZR-MD-001, is a selenium sulfide-based ointment applied to the lower eyelid for the treatment of Meibomian Gland Dysfunction (MGD). Through blinking, the ointment distributes to the upper lid, where it helps soften gland blockages, decrease abnormal keratin production, and enhance meibum quality. The therapy is currently in Phase III clinical trials evaluating its safety and effectiveness in MGD patients.
Meibomian gland dysfunction Companies
More than four key companies are actively pursuing therapies for Meibomian Gland Dysfunction (MGD), with Azura Ophthalmics at the forefront, advancing a lead candidate now in Phase III clinical trials.
DelveInsight's report covers around 4+ products under different phases of Meibomian gland dysfunction clinical trials like
*
Meibomian gland dysfunction Late stage Therapies (Phase III)
*
Meibomian gland dysfunction Mid-stage Therapies (Phase II)
*
Meibomian gland dysfunction Early-stage Therapies (Phase I)
*
Meibomian gland dysfunction Pre-clinical and Meibomian gland dysfunction Discovery stage Therapies
*
Meibomian gland dysfunction Discontinued & Inactive Therapies
Meibomian gland dysfunction pipeline report provides the Meibomian gland dysfunction therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as
*
Intravenous
*
Subcutaneous
*
Oral
*
Intramuscular
Meibomian gland dysfunction Products have been categorized under various Molecule types such as
*
Monoclonal antibody
*
Small molecule
*
Peptide
Download Sample Pages to Get an in-depth Assessment of the Emerging Meibomian gland dysfunction Therapies and Key Meibomian gland dysfunction Companies: Meibomian gland dysfunction Clinical Trials and recent advancements [https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Meibomian gland dysfunction Pipeline Therapeutic Assessment
- Meibomian gland dysfunction Assessment by Product Type
- Meibomian gland dysfunction By Stage
- Meibomian gland dysfunction Assessment by Route of Administration
- Meibomian gland dysfunction Assessment by Molecule Type
Download Meibomian gland dysfunction Sample report to know in detail about the Meibomian gland dysfunction treatment market @ Meibomian gland dysfunction Therapeutic Assessment [https://www.delveinsight.com/sample-request/meibomian-gland-dysfunction-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
Table of Content
1. Report Introduction
2. Executive Summary
3. Meibomian gland dysfunction Current Treatment Patterns
4. Meibomian gland dysfunction - DelveInsight's Analytical Perspective
5. Therapeutic Assessment
6. Meibomian gland dysfunction Late-Stage Products (Phase-III)
7. Meibomian gland dysfunction Mid-Stage Products (Phase-II)
8. Early Stage Products (Phase-I)
9. Pre-clinical Products and Discovery Stage Products
10. Inactive Products
11. Dormant Products
12. Meibomian gland dysfunction Discontinued Products
13. Meibomian gland dysfunction Product Profiles
14. Meibomian gland dysfunction Key Companies
15. Meibomian gland dysfunction Key Products
16. Dormant and Discontinued Products
17. Meibomian gland dysfunction Unmet Needs
18. Meibomian gland dysfunction Future Perspectives
19. Meibomian gland dysfunction Analyst Review
20. Appendix
21. Report Methodology
Request the Sample PDF to Get Detailed Insights About the Meibomian gland dysfunction Pipeline Reports Offerings [https://www.delveinsight.com/report-store/meibomian-gland-dysfunction-pipeline-insight?utm_source=abnewswire&utm_medium=market&utm_campaign=kpr]
About DelveInsight
DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Kritika Rehani
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=meibomian-gland-dysfunction-pipeline-analysis-clinical-trials-2025-delveinsight-azura-ophthalmics-santen-pharmaceutical]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/
Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com
This release was published on openPR.
Permanent link to this press release:
Copy
Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.
You can edit or delete your press release Meibomian gland dysfunction Pipeline Analysis & Clinical Trials, 2025, DelveInsight | Azura Ophthalmics, Santen Pharmaceutical here
News-ID: 4178156 • Views: …
More Releases from ABNewswire
Early Atlanta Heat Puts New Focus on Shade: Softek Awnings Designs Site-Specific …
With Atlanta recording its earliest 90-degree day on record in 2026 and summer nights trending warmer over the long term, Softek Awnings designs permanent shade around each property to help homeowners and businesses keep outdoor spaces usable through the hottest months.
ATLANTA - Aug 25, 2026 - An unusually early start to Atlanta's summer heat is putting renewed attention on permanent outdoor shade for homes and businesses. Atlanta reached 90 degrees…
Denver Laundry Service Expands Convenient Laundry Pickup and Delivery Across Den …
Denver Laundry Service is expanding access to convenient laundry pickup and delivery throughout Denver, offering professional wash and fold, commercial laundry, Airbnb laundry, linen cleaning, and dry cleaning services for residents and businesses. With free pickup and delivery, flexible scheduling, and next-business-day turnaround available for most wash and fold orders, the company provides a convenient alternative to traditional laundry routines.
DENVER, CO - August 25, 2026 - Denver Laundry Service [https://denverlaundryservices.com/]…
Dongguan Kaizhida Expands CNC Precision Machining Solutions to Support Complex a …
DONGGUAN, China - August 25, 2026 - Dongguan Kaizhida Precision Machinery Co., Ltd. (KZD), a provider of custom manufacturing services, is strengthening its CNC precision machining [https://www.kzd-cncmachining.com/] capabilities to help international customers transform complex designs into reliable, production-ready components. By combining advanced equipment, experienced engineering support, diverse material options, and comprehensive quality control, the company serves businesses seeking accuracy, consistency, and flexibility across prototype and volume-production projects.
As products become smaller,…
Kitchen Remodel Near Me Launches Nationwide Website Connecting Homeowners With L …
Kitchen Remodel Near Me launches a nationwide website connecting homeowners with independent local professionals for full kitchen renovations, cabinet installation, countertop upgrades, layout improvements, flooring and backsplashes.
New Jersey, United States - August 25, 2026 - Kitchen Remodel Near Me today announced the launch of remodelkitchennearme.com [https://remodelkitchennearme.com/], a nationwide website designed to help homeowners connect with independent local kitchen remodeling professionals.
The website provides a centralized starting point for homeowners planning a…
More Releases for Meibomian
Meibomian Gland Dysfunction Market Report Examines Industry Trends, Growth Drive …
Understanding the future outlook of the meibomian gland dysfunction market reveals promising growth prospects fueled by advancements in treatment options and increasing awareness of eye health. This overview explores the market's expected valuation, key players, emerging trends, and detailed segmentation to provide a comprehensive understanding of this expanding medical sector.
Projected Market Value and Growth of the Meibomian Gland Dysfunction Market
The meibomian gland dysfunction market is anticipated to experience…
Analysis of Key Market Segments Influencing the Meibomian Gland Dysfunction Mark …
The meibomian gland dysfunction market is poised for significant growth over the coming years, driven by advancements in treatment options and increased awareness of eye health. As demand for personalized and device-assisted therapies rises, the market is set to expand steadily, presenting new opportunities for innovation and improved patient care.
Growth Projections of the Meibomian Gland Dysfunction Market by 2030
The market for meibomian gland dysfunction is anticipated to reach…
Meibomian Gland Dysfunction Market Trends, Treatments, and Forecast
Meibomian Gland Dysfunction (MGD) is a condition that affects the meibomian glands, which are responsible for producing the oily layer of tears that prevent the evaporation of tears and help lubricate the eyes. MGD leads to an inadequate tear film, resulting in dry eye symptoms, irritation, inflammation, and discomfort. It is a common cause of dry eye disease (DED), particularly in older adults, and its prevalence is expected to rise…
The connection between Chinese children's Meibomian Gland Dysfunction and dry ey …
Meibomian gland dysfunction (MGD) is one of the most common causes of dry eye disease (DED), a condition affecting millions globally. MGD occurs when the meibomian glands, located in the eyelids, fail to secrete enough oil or produce poor-quality oil, leading to rapid tear evaporation. The result is ocular discomfort, irritation, redness, and blurred vision.
Download Full PDF Sample Copy of Market Report @ https://exactitudeconsultancy.com/request-sample/72867
Rising screen time, environmental stressors, and aging…
Meibomian Gland Dysfunction Market Expected to Achieve 6.7% CAGR by 2029: Growth …
Use code ONLINE30 to get 30% off on global market reports and stay ahead of tariff changes, macro trends, and global economic shifts.
How Large Will the Acne Treatments Market Size By 2025?
In recent times, the acne treatments market has experienced a robust growth. The projection is that it will expand from $8.29 billion in 2024 to $8.81 billion in 2025, representing a compound annual growth rate (CAGR) of 6.3%. The…
U.S. Meibomian Gland Dysfunction Market Set to Witness Robust Expansion - Pfizer …
U.S. Meibomian Gland Dysfunction Market Insights
The U.S. Meibomian Gland Dysfunction Market encompasses a broad portfolio of therapeutic options, including ocular lubricants, anti‐inflammatory agents, antibiotics, and innovative thermal pulsation devices designed to restore lipid layer secretion and improve tear film stability. These products offer advantages such as reduced corneal irritation, improved patient comfort, and decreased dependency on artificial tears. With the growing prevalence of dry eye disease driven by extensive screen…
